Drug Detail

Information about AYVAKIT

Generic Name	Avapritinib
IND	BLU-285
Brand Name (US)	AYVAKIT
Manufacturer	Blueprint Medicines
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Approved for GISTS with PDGFRA exon 18 mutations
Indications	GIST, SM
Overall Strategy	KIT Protein Based
Strategy	Block KIT/PDGFRA
Drug Category	KIT/PDGFRA inhibitor + D842V inhibitor

Avapritinib is FDA approved for treatment of adults with unresectable or metastatic GISTs that have mutations in PDGDFRA exon 18 including the D842V mutation.
It is approved for patients in any line of treatment, for example, 1st line, 2nd line, etc., but it is not approved for adjuvant treatment (preventative).